Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
UNC5A
has been reported to be related with human cancers. However, the function and mechanism in non-small cell
lung carcinoma
(NSCLC) remains unknown. We analyzed two NSCLC cell lines (A549 and H157), one normal human bronchial epithelial cell line (BEAS-2B) and the tissues of NSCLC. We used quantitative real-time PCR (qRT-PCR), western blot and immunohistochemical (IHC) staining to examine the expression of
UNC5A
. Methylation status of the
UNC5A
promoter was analyzed using methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP). We used western blot to analyzed protein levels of PI3K/Akt pathway. We found that the mRNA expression of UNCA5 was significantly downregulated in NSCLC cells and tissues. The promoter of
UNC5A
was hypermethylated in NSCLC cells compared to normal control cells. The expression of
UNC5A
could be reversed by demethylation agent in NSCLC cells. The expression of
UNC5A
was decreased in NSCLC samples and significantly associated with the advanced types of NSCLC. Functionally, knockdown of
UNC5A
promoted cell proliferation, migration, invasion and induced apoptosis in NSCLC, overexpression of
UNC5A
yielded the opposite result. Moreover, we found that
UNC5A
negatively regulated PI3K/Akt signaling pathway in NSCLC.
UNC5A
is a novel epigenetically silenced gene in NSCLC and consequent under-expression of
UNC5A
may contribute to NSCLC tumorigenesis through regulating PI3K/Akt pathway.
...
PMID:UNC5A, an epigenetically silenced gene, functions as a tumor suppressor in non-small cell lung cancer. 3310 Aug 60
